中旗股份 reported revenue of ¥1.55B for the period ended 2026-06-30, +16.2% year on year. Net income was ¥0.05B, a 3.5% net margin on a 15.8% gross margin. The largest revenue line is 农药原药 at 77% of the total. Free cash flow for the period was ¥-0.03B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥1.55B | +16.2% |
| Gross profit | ¥0.24B | — |
| Operating income | ¥0.06B | — |
| Net income | ¥0.05B | — |
| Gross margin | 15.8% | Net margin 3.5% |
| Revenue Q/Q | +38.4% | — |
| Segment | Revenue | Share |
|---|---|---|
| 农药原药 | ¥1.19B | 76.7% |
| 农药制剂 | ¥0.14B | 9.3% |
| 贸易收入 | ¥0.14B | 9.2% |
| 农药中间体 | ¥0.06B | 3.8% |
| 其他 | ¥0.02B | 1.0% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥1.30B | 84.2% |
| R&D | ¥0.04B | 2.8% |
| SG&A | ¥0.09B | 5.7% |
| Tax & other | ¥0.01B | 0.6% |
| Item | Amount |
|---|---|
| Total assets | ¥4.82B |
| Total liabilities | ¥2.71B |
| Shareholders' equity | ¥2.11B |
| Equity / assets | 43.7% |
| Operating cash flow | ¥-0.01B |
| Capital expenditure | ¥0.02B |
| Free cash flow | ¥-0.03B |
| Cash conversion (OCF / net income) | 306% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
容大感光 ・ 开润股份 ・ 会畅科技 ・ 数字认证 ・ 贝斯特 ・ 晨曦航空 ・ 英飞特 ・ 赛托生物 ・ 海辰药业 ・ 奥联电子 ・ 美联新材 ・ 天铁科技
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies